Brandtree

Who owns Austedo?

Austedo is owned by Teva (Israel, NYSE: TEVA).[1]

Evidence: Teva Pharmaceutical Industries Limited Annual Report on Form 10-K filed 2026-02-03, SEC EDGAR, 3 February 2026. Verified from filings; last checked .

Key facts

Current owner
Teva Pharmaceutical Industries Limited verified
Owner HQ
🇮🇱 Israel, Tel Aviv
Origin
🇮🇱 Israel
Founded
2017
Category
Healthcare & pharma › Drug makers › Pharmaceuticals
Parent ticker
NYSE: TEVA
Last verified
· 1 sources

About Austedo

Austedo (deutetrabenazine) is a Teva medicine for chorea associated with Huntington's disease and for tardive dyskinesia, a movement disorder that can follow certain psychiatric and gastrointestinal drugs. It launched in the United States in 2017, and a once-daily extended-release version, Austedo XR, reached the market in May 2023. In 2025 Teva and Medicare negotiated a maximum fair price for it.

How often Teva names Austedo in its annual report

A plain count of the times the name appears in the text of each annual report, not counting the start of a sentence. A brand that an owner writes about more is usually one it treats as central.

Annual report filedTimes Austedo is named
20260
20252
20240

Ownership timeline of Austedo

Owners of Austedo over 2017 to 2026 Teva start not recorded–present Teva (start not recorded) 20172018201920202021202220232024202520262027
  1. Current owner Teva [1] verified

Where Austedo sits in Teva

Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.

Where Austedo sits in Teva Tree of 4 brands under Teva. Teva Austedo Ajovy Copaxone Uzedy

Open the full Teva ownership tree →

See the full Teva brand portfolio (4) →

Other brands owned by Teva

Teva controls 4 brands on Brandtree, 4 of them in healthcare & pharma.

Also in healthcare & pharma

All Teva brands →

Other brands in pharmaceuticals, and who owns them

Teva has more brands in pharmaceuticals on Brandtree than any other owner: 4 of 13.

BrandOwnerOwner based in
Celebrex Viatris 🇺🇸 United States
Brekiya Amneal 🇺🇸 United States
Evra Richter 🇭🇺 Hungary
Habitrol Dr. Reddy's 🇮🇳 India
Lipitor Viatris 🇺🇸 United States
Lyrica Viatris 🇺🇸 United States
Viagra Viatris 🇺🇸 United States
Rytary Amneal 🇺🇸 United States

Every brand in pharmaceuticals and its owner →

About the owner: Teva

Teva is a publicly listed company headquartered in Tel Aviv, Israel. Brandtree records 4 brands under its control, and it is listed as NYSE: TEVA.

Teva is an Israeli-domiciled pharmaceutical company that sells generic medicines worldwide alongside a growing list of branded innovative drugs. Its 2025 annual report puts the weight of its strategy on four products: AUSTEDO for movement disorders, AJOVY for migraine, UZEDY for schizophrenia and bipolar disorder, and COPAXONE for multiple sclerosis. Its United States operations are run from Parsippany, New Jersey.

Teva: full profile, brands and acquisition history →

🇮🇱 Austedo and other Israeli brands

Brandtree records a controlling owner for 52 brands that began in Israel. 3 of them (6%) are now controlled by a company headquartered in another country; Austedo is not one of them.

All Israeli brands and who owns them →

Frequently asked questions

Who is the parent company of Austedo?

The parent company of Austedo is Teva, a publicly listed company headquartered in Israel.

Is Austedo Israeli?

Yes. Austedo originated in Israel in 2017 and its owner, Teva, is also headquartered in Israel.

Is Austedo still owned by Teva?

Yes. As of 10 October 2026, Austedo is still owned by Teva. The ownership record was last checked against primary sources on that date.

Sources (1) & corrections

Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.

  1. [1] Teva Pharmaceutical Industries Limited Annual Report on Form 10-K filed 2026-02-03 — SEC EDGAR, SEC Form 10-K, published 3 February 2026; retrieved 10 October 2026.

Report a correction Opens a pre-filled GitHub issue. See our corrections policy.